Catalyst Wire Dossier Catalyst Wire Dossier

rAd-IFN

recombinant adenovirus interferon
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for rAd-IFN, covering 2025-05-20 to 2025-05-20. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma [Phase 3]

See pricing